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Introduction. Glioblastoma multiforme (GBM) is the most common primary brain tumor in adults, is an aggressive malignancy
with a poor outcome. Current standard of care for newly diagnosed GBM includes trimodality treatment (Surgery, concomitant
Radiotherapy and Chemotherapy).
Objective. The aim of this study was to investigate if the demonstrated improved survival in the literature is translated to clinical
practice.
Materials and methods. This is a retrospective study between June 1996 and February 2013 that includes 163 patients with GBM.
Median age 62 years (24–87); 102 male (62.6%) and 61 female (37.4%); 63 patients (38.6%) received 2DCRT and 100 (61.4%) were
treated with 3DCRT. Performance status (PS-ECOG) 0=7.4% of the patients; 1 = 39.9%; 2=33.7%; 3=13.7%; 78 patients (47.9%)
had complete tumor resection, 59 (47.6%) incomplete resection and 18 (11%) received only biopsy; 147 patients (93%) received
chemotherapy, BCNU in 26 patients, Temozolamide (TMZ) concomitant in 12, TMZ concomitant and adjuvant 109. The Temporal
lobe (41.4%), right hemisphere (52.5%), unilobar localization (66.9%) were the most common sites affected. For survival analysis
patients were stratiﬁed by age, ECOG, and treatment modalities.
Results. The mean overall survival (mOSV) was 19.7 months (95% CI: 16.4–23.0); and mean progression-free survival (mPFSV) was
13.3 months (95% CI: 9.8–16.7) for the whole group. At 1 year mOSV was 54%, 2 years 25%, 3 years 13%, 4 years 10% and 6% at 5
years. The mPFSV at 1 year was 32%, 2 years 11%, 3 years 8%, 4 years 3% and 1% at 5 years. Factors identiﬁed as predictors of better
overall survival (OS) were: extent of resection (p=0.000 Log Rank); ECOG 0 vs. 1–3 (p=0.031 Long Rank) and type of chemotherapy
TMZ vs. BCNU (p=0.006 Log Rank). On the other hand: 3DCRT vs. 2DCRT (p=0.644 Long Rank), Sex (p=0.79 Long Rank), and age
of diagnosis (p=0.351 Long Rank), were not factors predictors of OS in our retrospective study.
Conclusions. Complete resections, TMZ associated with 3DCRT, ECOG 0 younger patients signiﬁcantly improve survival.
http://dx.doi.org/10.1016/j.rpor.2013.03.131
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Introduction. The reirradiation of a local relapse remains nowadays a challenge for the tumor control of patients diagnosed with
Glioblastoma Multiforme (GBM). It is not unusual that patients receive QT-RT after a surgical resection, with the underlying
effects, what makes even more difﬁcult to design the proper treatment for the patient, due to the previous treatments.
Objectives. To compare the different PTV coberture in the different planning techniques in two different patients: one treated
with 3DCRT versus another patient treated with IMRT.
Methods. Two patients diagnosed with a relapse of GBM, underwent Radiotherapy after a surgical resection of the tumor failure,
previously treated with QT-RT (Temozolamide plus 60Gy with 3DCRT) after surgical resection. Patient A: 24 year-old patient
received a total dose treatment of 37.5Gy, delivered in 15 sessions of 2.5Gy per fraction with 3DCRT. Patient B: 41 year-old patient
received a total dose treatment of 36Gy, delivered in 20 sessions of 1.8Gy per fraction with IMRT.
Results. Patient A: Radiation Technique: 3DCRT V95: 99.94%/V100: 78.82% D95: 36.7Gy/D100: 35.35Gy/Tronco: Dmáx: 5Gy, Dmedia:
1.16Gy Vías ópticas: Dmáx: 1.2Gy, Dmedia: 1Gy Patient 2: Radiation Technique: IMRT V95: 99.97%/V100: 91.05% D95: 35.65%/D100:
33.67%/Tronco: Dmáx: 35.07%, Dmedia: 19.91Gy Vías ópticas: Dmáx: 13.72Gy/Dmedia: 11.3 Gy.
Conclusions. We conclude that, although the planning comparison is between two different patients, the IMRT achieved a better
PTV coberture than 3DCRT with a good sparing of the OARs and eloquent areas.
http://dx.doi.org/10.1016/j.rpor.2013.03.132
Glioblastoma Multiforme: Reirradiation planning techniques comparison in the same patient
P. Soler Catalán1, J. Morales Marco1, F. Andreu Martínez1, R. Tortosa Oliver2, N. Chinillach Ferrando2
1 Hospital Imed Elche, Oncología Radioterápica, Spain
2 Hospital Imed Elche, Unidad de Radiofísica, Spain
Introduction. Nowadays, patients diagnosed with Glioblastoma Multiforme (GBM) can be treated with different radiotherapy
techniques depending on the available technology of each radiation oncology department.
Objectives. To analyse the best treatment option with radiotherapy on a patient with several tumor control failures, previously
treated with surgery, surgery plus QT-RT and a new scheme of surgery plus QT-RT.
Methods. A 41-year-old patient diagnosed with GBM in 2003, who was operated with R0 without adjuvant treatment. Five years
later, the patient underwent a second surgery for a local relapse. Adjuvant treatment with QT-RT was delivered (Temozolamide
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plus 60Gy with 3DCRT). In 2012, a new relapse was operated on subtotal surgery to avoid sensitive aphasia (as seen on post-
surgery MRI) We compared a total dose treatment of 36Gy, delivered in 20 sessions of 1.8Gy per fraction with 3DCRT, IMRT and
RapidArc®.
Results. 3DCRT: V95: 91%/V100:61% D95: 33.6Gy/D100: 28.8Gy/Brainstem: Dmaximum: 35Gy, Dmedian: 18Gy Visual pathways:
Dmaximum: 28.2Gy, Dmedian: 19Gy IMRT: V95: 99.97%/V100: 91.05% D95: 35.65%/D100: 33.67%/Brainstem: Dmaximum: 35.07%,
Dmedia: 19.91GyVisual pathway:Dmaximum: 13.72Gy/Dmedian: 11.3GyRAPIDARC:V95: 99.98%/V100: 91.8%D95: 35.42Gy/D100:
33.16Gy/Brainstem: Dmaximum: 36.13Gy, Dmedian: 17.4Gy Visual pathway: Dmaximum: 12.7Gy/Dmedian: 10.13Gy.
Conclusions. We conclude that the three techniques analysed can achieve good cobertures of PTV, sparing the different OARs and
eloquent areas.
http://dx.doi.org/10.1016/j.rpor.2013.03.133
Malignant tumors of the central nervous system (CNS). Our experience
N. Gascón1, V. Rodríguez1, S. Guardado1, S. Gómez1, C. Lechuga1, M. Martín1, M. Casado1, Ó. Hernández1,
V. Fernández2, J. Pérez-regadera1
1 Hospital Universitario 12 de Octubre, Oncología Radioterápica, Spain
2 Hospital Universitario 12 de Octubre, Radiofísica, Spain
Introduction. The high degree glial tumors account for 2% of neoplasms in accident. They are aggressive tumors that require
multidisciplinary approach with surgery, radiotherapy and chemotherapy.
Objective. Analyzed, in a retrospective series of malignant glial tumors, treatments performed, results and acute and chronic
morbidity resulting therefrom.
Material and methods. Between February 2008 and February 2012 we evaluated 109 patients with primary CNS malignancies (54%
male and 46% female) with a median age of 61 years. Glioblastoma Multiforme were 82%, 11% Anaplastic Astrocytoma, 3%
Anaplastic Oligoastrocytoma, 4% Anaplastic oligodendroglioma and 6% histological conﬁrmation could not be obtained so it was
based on imaging test. 94% of patients were operated: 28% by total resection, 47% by partial resection and 19% exclusive biopsy.
97% of patients received adjuvant treatment: 84% RT+QT (Stupp scheme), 8% exclusive RT, 6% RT+QT in clinical trial and 3%
none. In 97% of patients we planned 3D CRT and in 3% Fractionated Stereotactic Radiotherapy. Median radical treatment dose
was 60Gy and 35Gy in palliative treatments.
Results. Median follow-up was 252 days. Toxicity assessed by CTCAE v4.0: of the 97 patients who received adjuvant treatment
with QT, 19% had thrombocytopenia≥grade II and 24%≥grade II leukopenia. 97% of them showed no memory impairment and
94% had no cognitive impairment. The surgical site failure occurred in 88% of patients, the remote failure occurred in 9% of
patients and 3% in both.
Conclusions. The high-grade glial tumors are tumors of poor prognosis with short survival being achieved discreetly extend thanks
to the combination of treatments.
http://dx.doi.org/10.1016/j.rpor.2013.03.134
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Purpose. To evaluate the survival of patients with newly diagnosed Glioblastoma Multiforme depending on the surgery performed.
Materials and methods. From April 2002 till January 2012, 82 patients (43 male and 39 female) mean age 63.3 (range from 29
to 82) with newly diagnosed Glioblastoma Multiforme was treated in our hospital. The treatment protocol consisted of total
surgery, partial surgery or biopsy only followed by external radiation therapy (6000 cGy in 30 fractions with conformal radio-
therapy technique) and concurrent chemotherapy with Temozolomide (75mg/m2/day) and adjuvant Temozolomide (TMZ)
monotherapy for 6 cycles (150–200mg/m2/5days). The median survival was evaluated depending on the type of surgery per-
formed. Total surgery was realized in twenty-nine patients (35.4%), ten patients (12.2%) were treated by partial surgery and
biopsy only was made in forty-three patients (52.2%). Survival was calculated using Kaplan–Meier and Long Rank (Mantel Cox)
methods.
Results. Overall survival for our patients was 14.5 months. Two patients who were diagnosed on April 2006 and December 2010
having undergone biopsy and total surgery respectively are still alive. Twenty-eight patientswere treated by total surgery followed
by concurrent chemotherapy–radiotherapy (QTRT) with TMZ and adjuvant TMZ with a median survival of 18 months. Partial
surgery followed by concurrent QTRT and adjuvant TMZ was realized in 10 patients with a median survival of 19.9 months.
Forty-two patients were not treated by surgery and received treatment which consisted of concurrent QTRT and adjuvant TMZ
with a median survival of 10.8 months. The longer survival was 68 months in a patient who was treated by total surgery followed
by concurrent QTRT and adjuvant TMZ. According to the Long Rank method a signiﬁcant median survival difference is observed
between biopsy and partial surgery with a p=0.016 and Biopsy and total surgery also, with a p=0.004. There is no difference
between total and partial surgery with a p=0.861.
